Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ho-Jae Lee | - |
dc.date.available | 2020-12-31T05:40:09Z | - |
dc.date.created | 2020-12-31 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 2288-3649 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79552 | - |
dc.description.abstract | TGF-β is a multifunctional cytokine that plays an important role in both physiologic and pathologic processes, including cancer. Importantly, TGF-β has a dual role in tumorigenesis, acting as a tumor suppressor or a tumor promoter, depending on the stage of tumor development. The aberrantly upregulated production of TGF-β has been strongly implicated in tumor progression, angiogenesis, and metastasis, as well as immune evasion. Therefore, hyperactivated TGF-β signaling is considered a potential therapeutic target for cancer therapy. Numerous inhibitors of overactivated TGF-β signaling have been developed, and some of them are currently in clinical trials. This review focuses on the TGF-β signaling that contributes to tumor progression and immune evasion in the tumor microenvironment and presents recent achievements on TGF-β signaling inhibition as a single or combined therapeutic approach in cancer therapy. Key Words TGF-b, Tumor microenvironment, Tumor escape, Antineoplastic agents, Immune checkpoint inhibitors | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한암예방학회 | - |
dc.relation.isPartOf | 대한암예방학회지 | - |
dc.title | Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy | - |
dc.title.alternative | Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.wosid | 000607679900003 | - |
dc.identifier.bibliographicCitation | 대한암예방학회지, v.25, no.4, pp.213 - 222 | - |
dc.identifier.kciid | ART002665276 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 222 | - |
dc.citation.startPage | 213 | - |
dc.citation.title | 대한암예방학회지 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Ho-Jae Lee | - |
dc.subject.keywordAuthor | TGF-b | - |
dc.subject.keywordAuthor | Tumor microenvironment | - |
dc.subject.keywordAuthor | Tumor escape | - |
dc.subject.keywordAuthor | Antineoplastic agents | - |
dc.subject.keywordAuthor | Immune checkpoint inhibitors | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.